LB Pharmaceuticals (LBRX) vs First Tracks Biotherapeutics (TRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
LB Pharmaceuticals is the larger company by market cap ($1.10 billion vs $1.09 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | TRAX |
|---|---|---|
| Share price | $34.16 | $30.59 |
| Market cap | $1.10B | $1.09B |
| 1-day change | -0.29% | -2.55% |
| YTD return | +53.46% | — |
| 1-year return | +113.37% | — |
| P/E ratio (TTM) | 341.60 | — |
| EPS (TTM) | $0.10 | $-4.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.16 | $49.91 |
| 52-week low | $14.32 | $14.72 |
| Distance from 52-week high | -31.90% | -38.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.74% | +128.83% |
| Average volume | 341.17K | 785.86K |
| Shares outstanding | 32.26M | 35.73M |
| Employees | 49 | 104 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About First Tracks Biotherapeutics
TRAX stock →First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees
LBRX vs TRAX FAQ
Which is bigger, LB Pharmaceuticals or First Tracks Biotherapeutics?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.10B compared with $1.09B for First Tracks Biotherapeutics (TRAX).
Are LB Pharmaceuticals and First Tracks Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.